CLINICAL_TRIALS ClinicalTrials.gov record update

A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03331562
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:51.452776+00:00
Published At: 2022-12-27T00:00:00+00:00
Record Updated At: 2022-12-27
Results Posted At: 2022-12-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pancreatic Cancer", "Pancreas Adenocarcinoma", "Advanced Pancreatic Cancer", "Metastatic Pancreatic Cancer", "Metastatic Pancreatic Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-12-27"
protocolSection.identificationModule.nctId: "NCT03331562"
protocolSection.identificationModule.officialTitle: "A SU2C Catalyst \u00ae Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-12-27"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.